| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Acrosomal proteinase acrosin. Cetraxate HCl is an inhibitor of acrosomal proteinase acrosin, with a Ki of 0.94 μM and an IC50 of 3.3 μM. Its anti-ulcer activity is related to its cytoprotective effects on the gastric mucosa. Cetraxate HCl is a mucoprotective, orally bioactive anti-ulcer agent with cytoprotective effects.
|
|---|---|
| ln Vitro |
Cetraxate HCl is a potent inhibitor of acrosomal proteinase acrosin. It has cytoprotective effects on the gastric mucosa. It improves gastric mucosal microcirculation, increases mucosal resistance, and inhibits the conversion of pepsinogen to pepsin. Cetraxate HCl improves gastric mucosal microcirculation and increases mucosal resistance.
|
| ln Vivo |
Cetraxate HCl is an orally bioactive anti-ulcer agent that has been used in the treatment of gastric ulcers. It produces a dose-related increase in mucosal blood flow. Its in vivo efficacy has been demonstrated in animal models and clinical use. Cetraxate HCl is an orally bioactive anti-ulcer agent with cytoprotective effects.
|
| Enzyme Assay |
Specific protocols for in vitro enzyme assays for Cetraxate HCl are not detailed. Its inhibition of acrosomal proteinase acrosin is measured using standard enzyme assay techniques. Cetraxate HCl is a potent inhibitor of acrosomal proteinase acrosin, with a Ki of 0.94 μM and an IC50 of 3.3 μM.
|
| Cell Assay |
Cellular assays for Cetraxate HCl involve studying its effects on gastric mucosal cells. Its cytoprotective effects can be assessed in cell culture models. Cetraxate HCl has cytoprotective effects on the gastric mucosa.
|
| Animal Protocol |
In vivo animal model protocols for Cetraxate HCl involve its administration to animal models of gastric ulcers to study its anti-ulcer and cytoprotective effects. Cetraxate HCl is an orally bioactive anti-ulcer agent that has been used in the treatment of gastric ulcers.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Cetraxate HCl is not available in the provided references. As an orally active compound, its PK properties would be evaluated in preclinical studies. Cetraxate HCl is an orally bioactive anti-ulcer agent.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Cetraxate HCl is not available in the provided references. As a medication, its safety profile has been established through clinical use.
|
| References |
|
| Additional Infomation |
Cetraxate HCl is a medication used for the treatment of gastric ulcers. It is an anti-ulcer and anti-gastritis agent with cytoprotective effects. Cetraxate HCl (CAS#: 27724-96-5) is a mucoprotective, orally bioactive anti-ulcer agent with cytoprotective effects.
|
| Molecular Formula |
C17H24CLNO4
|
|---|---|
| Molecular Weight |
341.8298
|
| Exact Mass |
341.139
|
| Elemental Analysis |
C, 59.73; H, 7.08; Cl, 10.37; N, 4.10; O, 18.72
|
| CAS # |
27724-96-5
|
| Related CAS # |
34675-84-8;27724-96-5 (HCl);
|
| PubChem CID |
34001
|
| Appearance |
White to off-white solid powder
|
| Density |
1.182g/cm3
|
| Boiling Point |
480.9ºC at 760mmHg
|
| Melting Point |
238-240ºC
|
| Flash Point |
244.6ºC
|
| Index of Refraction |
1.551
|
| LogP |
3.876
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
369
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl[H].O(C1C([H])=C([H])C(C([H])([H])C([H])([H])C(=O)O[H])=C([H])C=1[H])C(C1([H])C([H])([H])C([H])([H])C([H])(C([H])([H])N([H])[H])C([H])([H])C1([H])[H])=O
|
| InChi Key |
USROQQUKEBHOFF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H23NO4.ClH/c18-11-13-1-6-14(7-2-13)17(21)22-15-8-3-12(4-9-15)5-10-16(19)20;/h3-4,8-9,13-14H,1-2,5-7,10-11,18H2,(H,19,20);1H
|
| Chemical Name |
3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic acid;hydrochloride
|
| Synonyms |
Cetraxate HCl; DV 1006; DV-1006; DV1006; Cetraxate hydrochloride.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~243.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9254 mL | 14.6272 mL | 29.2543 mL | |
| 5 mM | 0.5851 mL | 2.9254 mL | 5.8509 mL | |
| 10 mM | 0.2925 mL | 1.4627 mL | 2.9254 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
